Understanding between the NIOSH Approval and Food & Drug Administration/Centre for Devices & Radiological Health

This Memorandum of Understanding (MOU) between the NIOSH approval and Food and Drug Administration (FDA), acting through its Centre for Devices and Radiological Health (CDRH), and the Centres for Disease Control and Prevention (CDC), acting through its National Institute for Occupational Safety and Health (NIOSH), National Personal Protective Technology Laboratory (NPPTL) (herein referred to as “the Agencies”), provides a framework for coordination and collaboration between the Agencies relating to their regulation of Surgical N95 Respirators and N95 Filtering Face piece Respirators (FFRs) used in healthcare settings (herein collectively referred to as “N95s”). 

• Operon Strategist has a team of trained professionals that work according to set standards and constantly upgrading their work techniques that assure meeting customer requirements timely and as per defined quality standards.

A planned procedure will assist with guaranteeing that the different regulatory exercises of every organization identified with N95s are smoothed out and fit whenever the situation allows. The goal of this MOU is to help decrease clashing and duplicative premarket forms for these devices with the goal that partners can without much of a stretch and consistently observe what steps must be taken to fulfil the appropriate administrative necessities.

In particular, this MOU (1) depicts the systems by which explicit data relating to N95s might be traded between the two Agencies and (2) gives a structure to effective and facilitated administrative oversight of N95s planned for use in medicinal services settings. Hazardous Atmosphere: Any climate containing a harmful or malady delivering gas, fume, dust, smoke, fog, or pesticide, either promptly or not quickly risky to life or wellbeing; or any oxygen-lacking air.

Healthcare Personnel (HCP): All persons, paid and unpaid, working in healthcare settings who have the potential for exposure to patients and/or to infectious materials, including body substances, contaminated medical supplies and equipment, contaminated environmental surfaces, or contaminated air.  HCP include, but are not limited to, physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual personnel, home healthcare personnel, and persons not directly involved in patient care (e.g., clerical, dietary, house-keeping, laundry, security, maintenance, billing, chaplains, and volunteers) but potentially exposed to infectious agents that can be transmitted to and from HCP and patients.

Healthcare Settings: Healthcare settings include, but are not limited to, acute-care hospitals; long-term care facilities, such as nursing homes and skilled nursing facilities; physicians’ offices; urgent-care centres, outpatient clinics; and home healthcare.  Examples of settings that are not included in this definition are schools and worksites.  However, elements of this MOU may be applicable to specific sites within non-healthcare settings where care is routinely delivered (e.g., a medical clinic embedded within a workplace or school))

This FDA action affects the NIOSH approval process and related activities for NIOSH-approved N95 respirators intended for use in healthcare.

• Redundant actions between the two agencies will be eliminated.

• Manufacturers will only have to submit an application to one agency (NIOSH), rather than two (NIOSH and FDA).

• NIOSH approval will continue to ensure these devices provide the expected performance levels, and are safe for their intended use.

• NIOSH approval will now evaluate the manufacturer’s test data for biocompatibility, flammability, and fluid resistance for conformity to relevant standards during its approval process, tasks previously performed by the FDA.
• The conformity assessment process will include post-market audits that will involve conducting required tests, including flammability and fluid resistance. NIOSH approval will conduct those tests for a sample of products in accordance with the appropriate federal and consensus standards to ensure the products continue to conform to the approved conditions.

Read More -  NIOSH approval

Contact details –

Phone no -  9325283428

Mail  - dm@operonstrategist.com

If  You Want Medical Devices Services Consultation For Following.

1. Medical Device Consulting 
2. cdsco registration 
3. FDA 510k Clearance 
4. ce mark medical device 
5. CDSCO Manufacturing License 
6. CDSCO import license 
7. TURNKEY PROJECT CONSULTANT 
8. medical device manufacturing 
9. iso 15378 certification 
10. 21 cfr part 210 and 211 
11. ISO 13485 Medical Device Consultant 
12. Primary Packaging Turnkey Project Consultant 
13. Clean Room Design Consultant 
14. manufacturing site conceptualization 
15. Market Analysis and feasibility for Medical Devices 
16. manufacturing plant layout design 
17. medical device design and development 
18. DMF file submission guideline 
19. 21 cfr part 820 
20. qms certification services 
21. capa management 
22. design control requirements 
23. medical device process validation 
24. combination product 
25. continuous improvement program 
26. Medical Device Compliance & Regulatory Services 
27. Cdsco India authorized agent for medical device